Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2018
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Bortezomib; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ARUMM
- Sponsors Celgene Corporation
- 02 Dec 2018 Planned primary completion date changed from 30 Dec 2017 to 12 Oct 2020.
- 20 Apr 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 27 Nov 2015 Planned End Date changed from 1 Jun 2020 to 1 Oct 2020, according to ClinicalTrials.gov record.